Ritov · Diabetes 2005 · Cross-sectional case-control study · n=31

Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes.

Cited 891 times in the scientific literature.

Level 4 - case-series / case-control

Cross-sectional comparative study with human tissue biopsies across small clinical groups.

PubMed 15616005 · doi:10.2337/diabetes.54.1.8 · record verified 2026-08-31

What was done

Percutaneous vastus lateralis muscle biopsies were obtained from 31 volunteers: 11 with type 2 diabetes, 12 age-, sex-, and weight-matched obese sedentary nondiabetic controls, and 8 lean controls. Subsarcolemmal and intermyofibrillar mitochondrial fractions were isolated by differential centrifugation and digestion techniques to measure electron transport chain activity, mitochondrial DNA content, and ultrastructure by transmission electron microscopy.

What was found

Overall electron transport chain activity was similar between type 2 diabetic and obese subjects. Subsarcolemmal mitochondrial electron transport chain activity was significantly lower in type 2 diabetic subjects compared to obese controls (0.017 ± 0.003 vs. 0.034 ± 0.007 units/mU creatine kinase, P = 0.01) and sevenfold lower compared to lean subjects (P < 0.01). Intermyofibrillar electron transport chain activity was similar in diabetic and obese subjects, though lower than in lean subjects. Transmission electron microscopy confirmed the reduction in subsarcolemmal mitochondria. While mtDNA was reduced in both diabetic and obese groups, the decrement in electron transport chain activity was proportionately greater.

Why it matters

This study shows that mitochondrial impairment in type 2 diabetic skeletal muscle is predominantly localized to the subsarcolemmal mitochondrial subpopulation, identifying a specific subcellular deficit that may contribute to muscle insulin resistance.

Limits

The study is limited by a small sample size (n = 31 total across three groups) and a cross-sectional design that cannot establish causality. Functional in vivo substrate oxidation, insulin signaling intermediates, and clinical metabolic outcomes were not reported in the abstract.

Cited by